Carmel Olefins After 2025: No Impairment, but Not Much Valuation Cushion Either
Carmel Olefins cleared the 2025 year-end impairment test without a write-down, but not with a clean comfort stamp. Activity value stands at $652.3 million against a $574.6 million carrying amount, while the 2026 EBITDA forecast is still negative and Haifa Bay risk is neutralized in the model through a full-compensation assumption.
No Impairment, but Not a Clean Bill of Health
The main article argued that Bazan is no longer stuck on whether the refinery can return to work. The bottleneck has moved downstream, especially into polymers. This continuation isolates the sharpest accounting proof of that point: Carmel Olefins' year-end 2025 impairment test.
At first glance, the headline looks reassuring. As of December 31, 2025, the recoverable amount of Carmel Olefins' assets was estimated at $652.3 million against a carrying amount of $574.6 million, so no impairment was recorded. But this test was not commissioned out of comfort. It was commissioned because of Carmel Olefins' performance, especially in the fourth quarter, and because of a negative update to the 2026 outlook.
The historical numbers of Carmel Olefins itself also do not look like a healthy base that simply passed with room to spare. Revenue fell in 2025 to $446.1 million from $602.1 million, and EBITDA moved to negative $11.3 million from positive $17.8 million in 2024. That happened even though Carmel Olefins recognized roughly $26 million of insurance income in 2025, described as about 75% of the business interruption claim. In other words, even after a meaningful insurance layer, the business still did not finish the year on comfortable footing.
This was not a comfort test. It was a test designed to explain why there is no write-down now even though the model already opens 2026 on a weak footing.
| Key metric | 30.6.2025 | 31.12.2025 | What it means |
|---|---|---|---|
| Activity value | 724.1 | 652.3 | Value fell by about $71.8 million in six months |
| Carrying amount | 646.5 | 574.6 | Book value fell by almost the same amount |
| Cushion above book | 77.6 | 77.7 | The buffer barely changed, it did not improve |
What Is Actually Holding the Model Up
The most important point here is not the absence of a write-down. It is the structure of the gap. In June 2025, value was estimated at $724.1 million against a carrying amount of $646.5 million. By December, value had fallen to $652.3 million and book value had fallen to $574.6 million. The cushion therefore barely moved, about $77.6 million in June and about $77.7 million in December.
That is the critical point. The year-end outcome does not say that Carmel Olefins moved out of the danger zone. It says that value and book both moved down almost in parallel, allowing the buffer above book to survive.
The EBITDA path embedded in the DCF also shows how little of this cushion rests on a strong near-term year. Carmel Olefins' forecast EBITDA in the impairment work is negative $24.0 million in 2026, only positive $7.3 million in 2027, then $58.4 million in 2028, $124.8 million in 2029, and $133.8 million in 2030. This is not a recovery that arrives quickly. It becomes visible only in the second half of the explicit forecast period.
There is another burden inside the same model. The forecast also assumes CAPEX of $15.7 million in 2026, $44.7 million in 2027, and $81.6 million in 2028, the year in which a major planned turnaround is expected. So even the year in which profitability starts to improve meaningfully is not a clean year. It is a year that still carries a large investment load.
This is an inference from the disclosed numbers rather than a direct quote, but it is the right one: most of the value in the model is not being carried by 2026, or really by 2027 either. It is being carried by the assumption that margins, volumes, and profitability bend back into shape from 2028 onward.
The Cushion Is More Sensitive Than the Headline Suggests
This is where the "no impairment" headline becomes less impressive. In the year-end sensitivity analysis, a 0.5% increase in the discount rate reduces value to $601.6 million. A $15 per ton decline in the weighted polymer margin in the representative year reduces value to $600.7 million. In both cases Carmel Olefins still remains above book, but only by about $26 million to $27 million.
That is already a narrow cushion. Not zero, but not one that allows for many mistakes.
The full valuation matrix shows something more important. If one combines a 9.0% discount rate with a $15 per ton lower weighted terminal margin, value falls to $553.8 million, which is $20.7 million below the carrying amount. In other words, the matrix itself already contains combinations under which the cushion disappears.
| Scenario | Activity value | Gap vs. carrying amount |
|---|---|---|
| Base case | 652.3 | 77.7 |
| Discount rate higher by 0.5% | 601.6 | 27.0 |
| Weighted margin lower by $15 per ton | 600.7 | 26.1 |
| Both changes together | 553.8 | (20.7) |
No write-down, but not much room for error either.
The Model Neutralizes Haifa Bay, It Does Not Solve It
One of the most important assumptions in the model is not only about polymer margins. It is about Carmel Olefins' future in Haifa Bay itself. The government is advancing a strategic Haifa Bay redevelopment plan that includes the cessation of Carmel Olefins' activity. In the impairment work, the assumption was that if this plan is implemented, the company would receive full compensation from the state equal to the activity value at that time, making the economic outcome equivalent. On that basis, the forecast assumes the plan will not be implemented in a way that affects value.
That is a major distinction. The accounting model does not say that the Haifa Bay risk disappeared. It says that the risk was neutralized for valuation purposes through a full-compensation assumption. The valuation report also states that KPMG did not examine that issue.
So anyone reading the absence of an impairment as proof that regulatory and planning risk is behind the company is reading the model too strongly. The model puts weight on margins, volumes, and discount rate. The question of whether, when, and on what terms petrochemical activity in Haifa Bay is shut down is largely routed around through the compensation assumption.
The Operating Evidence Around It Is Not Clean Either
The impairment test does not stand alone. It sits inside a wider operating evidence set, and that set is not clean either. The broader polymers segment ended 2025 with negative EBITDA of $29 million after positive EBITDA of $9 million in 2024. In the fourth quarter alone, the segment was already at negative EBITDA of $30 million. Polymer output fell to 471 thousand tons from 639 thousand tons, mainly because Carmel Olefins operated only partially after the missile attacks and because Ducor went through scheduled turnarounds.
Inventory is also signaling pressure. By year-end 2025, the group recognized a $9 million write-down on Carmel Olefins polymer products and another $5 million on aromatics products. This is not a group-threatening event, but it is another sign that weakness in polymers has already moved beyond current earnings.
Ducor adds another layer. In June 2025 it recorded an $8 million impairment after recoverable amount was estimated at $46 million against a carrying amount of $54 million. No additional impairment was recorded at year-end, but the stated reason was not a clear market improvement. Instead, the company decided to change the way the asset is used, lowering the operating rate of its production lines to a level aligned with customer commitments and reducing spot exposure.
That matters because it is defensive behavior. The group is not acting as if the full polymers chain is already out of trouble. It is adjusting run rates, cutting spot exposure, and relying on the ability to bring production lines back to full operation within one to two weeks if conditions improve.
Conclusion
Carmel Olefins' year-end 2025 impairment test ends without a write-down, but not with comfort. Value remains above book, yet only by about $77.7 million, almost the same buffer that existed mid-year. The 2026 forecast is already negative, 2027 is still very thin, and the meaningful recovery is pushed mainly into 2028 to 2030.
The analytical implication is that the headline "no impairment" is accounting-true but economically weak. To read it as real relief, one has to believe not only in a recovery in margins and volumes, but also in the full-compensation assumption around Haifa Bay, and in a broader polymers layer that stops producing pressure signals such as inventory write-downs and defensive operating resets at Ducor.
The thesis here is not that Carmel Olefins is sitting on the edge of an inevitable write-down. The thesis is more precise: Carmel Olefins exited 2025 without an impairment, but also without much valuation cushion. If 2026 disappoints even moderately, this line item can move back to the center of the story quickly.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.